Showing 5081-5090 of 21466 results for "".
- PRP or Bmac Added To ACL Reconstruction Shows No 2-Year Benefithttps://reachmd.com/news/prp-or-bmac-added-to-acl-reconstruction-shows-no-2-year-benefit/2487786/Key Takeaways Platelet-rich plasma and bone marrow aspirate concentrate were not associated with better clinical outcomes at about 2 years after ACL reconstruction. MRI signal intensity of the intra-articular graft and the tunnel graft did not differ s
- Two-Year Outcomes in the PHARRLAP Rehabilitation Trialhttps://reachmd.com/news/two-year-outcomes-in-the-pharrlap-rehabilitation-trial/2487761/Key Takeaways Two-year recovery trajectories were broadly similar between groups after repair for acute avulsion involving at least 2 tendons. Accelerated rehabilitation was associated with a better 3-month SF-12 physical score and lower hamstring pain
- Ensartinib After Resection in Alk-Positive NSCLChttps://reachmd.com/news/ensartinib-after-resection-in-alk-positive-nsclc/2487759/Key Takeaways In stage II to IIIB disease, ensartinib was associated with a hazard ratio of 0.20 for recurrence or death versus placebo. A similar disease-free survival advantage was reported in the overall randomized population at 24 months.
- Prophylactic Dextrose Gel and School-Age Neurocognitive Outcomeshttps://reachmd.com/news/prophylactic-dextrose-gel-and-school-age-neurocognitive-outcomes/2487766/Key Takeaways School-age neurocognitive impairment was similar in children assigned to dextrose gel and placebo. Exploratory analyses found more emotional-behavioral difficulty and lower psychosocial function in the dextrose gel group. The inv
- Tamsulosin Deprescribing in Older Men With Lower Urinary Tract Symptomshttps://reachmd.com/news/tamsulosin-deprescribing-in-older-men-with-lower-urinary-tract-symptoms/2487765/Key Takeaways Investigators categorized 36.7% as having minimal or no effect, 36.7% as having a moderate effect, 13.3% as having a strong effect, and 13.3% as not tolerating the placebo run-in. Daily AUASI-based symptom tracking was used in a placebo-c
- Primary Care CGM Linked to Better HbA1c and Fewer Acute Visitshttps://reachmd.com/news/primary-care-cgm-linked-to-better-hba1c-and-fewer-acute-visits/2487758/Key Takeaways Primary care CGM initiation was associated with larger 12-month HbA1c declines, with reductions of 0.66 percentage points among initiators and 0.17 percentage points among noninitiators. CGM initiation was also associated with lower risk
- Menopausal Hormone Therapy and Long-Term Mortality in a Danish Cohorthttps://reachmd.com/news/menopausal-hormone-therapy-and-long-term-mortality-in-a-danish-cohort/2487749/Key Takeaways Adjusted analyses did not indicate higher long-term all-cause mortality among women who used systemic menopausal hormone therapy. Overall cause-specific analyses did not show unequivocal differences in cardiovascular, cancer, or other-cau
- Sirolimus-Eluting Balloon Strategy Versus Routine DES in De Novo Lesionshttps://reachmd.com/news/sirolimus-eluting-balloon-strategy-versus-routine-des-in-de-novo-lesions/2487757/Key Takeaways At 1 year, target vessel failure was reported in 5.3% of patients with the sirolimus-eluting balloon strategy and 4.4% with systematic DES implantation, and noninferiority was met in the intention-to-treat analysis. Bailout stenting was r
- Aurenar Wins FDA Breakthrough Designation for V-Linkhttps://reachmd.com/news/aurenar-fda-breakthrough-v-link/2487710/Key Takeaways The FDA granted Breakthrough Device Designation to Aurenar’s V-Link System for adults with aneurysmal subarachnoid hemorrhage as an ICU adjunct intended to reduce cerebral vasospasm. V-Link remains investigational while development, comme
- Sequential Add-On Therapy and Risk Reclassification in PAHhttps://reachmd.com/news/sequential-add-on-therapy-risk-reclassification-pah/2487709/Key Takeaways Both noninvasive risk tools shifted toward lower-risk categories during follow-up after macitentan was added to prior sildenafil. WHO functional class improved and BNP decreased, while 6-minute walk distance remained essentially unchanged